TGThomas D. Geracioti

Thomas D. Geracioti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Thomas D. Geracioti has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 January 2013
      • Vol. 16  (1) , E25-30

    Cigarette smokers have reduced risk for post-dural puncture headache.

    by Heather S Dodge, Nosakhare N Ekhator, Lena Jefferson-Wilson, Mark Fischer, Ian Jansen, Paul S Horn, William E Hurford, Thomas D Geracioti

    Although headache is the most common complication of dural puncture, knowledge gaps remain about patient-related risks. Data are lacking on the role, if any, of tobacco smoking, race, anxiety, depression, and Post Traumatic Stress Disorder (PTSD) in conferring risk for post-dural puncture headache (PDPH). To determine the influence of tobacco smoking, race, anxiety,depressed mood, and PTSD on the risk for PDPH. Retrospective chart review, single site. We determined the incidence of significant PDPH according to age, sex, race, smoking status, and psychiatric diagnosis in 153 consecutive research patients at the Cincinnati Veterans Affairs Medical Center who had continuous cerebrospinal fluid (CFS) sampling performed after using a large-bore (17 gauge) Tuohy needle to place a 20-gauge polyamide catheter in the lumbar spinal canal. Thirty-nine subjects (25.5%) had significant PDPH, defined as requiring an epidural blood patch for therapy (an average of 4 days post-procedure). Greater age was associated with a decreased risk of PDPH (P = 0.008); subjects over the age of 40 had the lowest incidence (15.7%). Women and men had a 31.4% and 23.7% incidence of PDPH, respectively; these were not significantly different (P = 0.38). Neither were rates of PDPH in Caucasians (28.0%) and African-Americans (15.6%) significantly different (P = 0.18) Healthy controls had a higher incidence of PDPH than patients with PTSD (P = 0.032). Smokers had a lower incidence of PDPH than non-smokers, 13.7% vs. 34.1% (P = 0.009). This was not a prospective study, rather a retrospective chart review. Most notably, smokers had a considerably reduced rate of PDPH in comparison with non-smokers. This information could be a useful addition to the clinical assessment of relative risk for PDPH. Further research into the mechanisms by which tobacco smoking may inhibit PDPH, such as nicotine stimulation of dopamine neurotransmission or alterations in coagulation, appears warranted.


  • Elevated Cerebrospinal Fluid Substance P Concentrations in Posttraumatic Stress Disorder and Major Depression

    by Thomas Geracioti, Linda Carpenter, Michael Owens, Dewleen Baker, Nosakhare Ekhator, Paul Horn, Jeffrey Strawn, Gerard Sanacora, Becky Kinkead, Lawrence Price, et al.

    The authors tested the hypothesis that concentrations of the pain-transmitting neuropeptide substance P are elevated in the CSF of patients with major depression or posttraumatic stress disorder (PTSD), which have overlapping symptoms. The authors also sought to determine if CNS substance P concentrations change on provocation of symptoms in PTSD patients. The authors measured CSF substance P concentrations in medication-free patients with either major depression or PTSD and in healthy comparison subjects. Next, using a within-subject, crossover design, the authors sampled CSF for 6 hours through an indwelling subarachnoid catheter in PTSD patients before, during, and after exposure to a 60-minute traumatic or neutral videotape stimulus. Both depressed and PTSD patients had significantly elevated basal CSF substance P concentrations. In the challenge study, marked increases in CSF substance P concentrations were found only after precipitation of PTSD symptoms. CSF substance P concentrations increased by 169% and 90.6% of baseline levels at 10 and 70 minutes, respectively, after the start of the traumatic videotape but changed by only 1.1% and -8.1% of baseline levels 10 and 70 minutes after the start of the neutral videotape. These results suggest that elevated CNS substance P concentrations are involved in both major depression and PTSD. The marked increase in CSF substance P concentrations during and after the symptom-provoking stimulus, but not after the neutral stimulus, implicates CNS release of substance P in the mechanism of acute PTSD symptoms. These data also reveal that CNS substance P responds acutely to psychological stress in humans.


  • Antithyroid Antibody-Linked Symptoms in Borderline Personality Disorder

    by Thomas D. Geracioti, Mitchel A. Kling, Robert M. Post, Philip W. Gold


  • CSF Norepinephrine Concentrations in Posttraumatic Stress Disorder

    by Thomas D. Geracioti, Dewleen G. Baker, Nosakhare N. Ekhator, Scott A. West, Kelly K. Hill, Ann B. Bruce, Dennis Schmidt, Barbara Rounds-Kugler, Rachel Yehuda, Paul E. Keck, et al.

    Despite evidence of hyperresponsive peripheral and central nervous system (CNS) noradrenergic activity in posttraumatic stress disorder (PTSD), direct measures of CNS norepinephrine in PTSD have been lacking. The goal of this study was to determine serial CSF norepinephrine levels in patients with PTSD. CSF samples were obtained serially over a 6-hour period in 11 male combat veterans with chronic PTSD and eight healthy men through an indwelling subarachnoid catheter. Thus the authors were able to determine hourly CSF norepinephrine concentrations under baseline (unstressed) conditions. Severity of the patients' PTSD symptoms was assessed with the Clinician-Administered PTSD Scale. CSF norepinephrine concentrations were significantly higher in the men with PTSD than in the healthy men. Moreover, CSF norepinephrine levels strongly and positively correlated with the severity of PTSD symptoms. Plasma norepinephrine concentrations showed no significant relationship with the severity of PTSD symptoms. These findings reveal the presence of greater CNS noradrenergic activity under baseline conditions in patients with chronic PTSD than in healthy subjects and directly link this pathophysiologic observation with the severity of the clinical posttraumatic stress syndrome.


  • The hypothalamic–pituitary–adrenal axis in aging: preclinical and clinical studies

    by Ajit Regmi, Dewleen G. Baker, James J. Mulchahey, John W. Kasckow, Marta Pisarska, Thomas D. Geracioti

  • Hormones, Gender and the Aging Brain

    by Mary F. Morrison, John E. Morley, Loretta M. Flanagan-Cato, Ajit Regmi, Dewleen G. Baker, James J. Mulchahey, John W. Kasckow, Marta Pisarska, Thomas D. Geracioti, Gabriel K. Tsuboyama, et al.

    The significance of hormone action in psychiatry has been long studied, now including the psychiatric effects of hormones on the aging process. This clinical reference addresses the hormonal basis of mental disorders in older people. Hormones influence a wide range of states and conditions, from pain tolerance and anorexia to attention, mood, immunity, cardiovascular and cognitive function, schizophrenia and Alzheimer's disease. Written by an eminent team of psychiatrists, psychologists, geriatricians and neuropharmacologists, this book brings together established information and findings in four sections:An overview of the basic science of neurosteroidsSex difference and the roles that cortisol, thyroid hormone, and the sex steroids estrogen, progesterone, dehydroepiandrosterone and testosterone play in common mental disorders and pain sensitivityPsychoneuroimmunology in relation to ageSex differences and hormones in psychotropic drug metabolism in the elderly.


  • Intra- and inter-individual correlations between cholecystokinin and corticotropin-releasing hormone concentrations in human cerebrospinal fluid

    by Thomas D. Geracioti, Nosa N. Ekhator, Wendell E. Nicholson, Stephan Arndt, Peter T. Loosen, David N. Orth

    Despite strong evidence of a physiologic relationship between cholecystokinin (CCK) and corticotropin‐releasing hormone (CRH) in the rat central nervous system (CNS), evidence of such a relationship between the two hormones in the human CNS is lacking. A post hoc analysis of serial concentrations of immunoreactive CCK and CRH, obtained every ten minutes from CSF continuously collected over six hours, was performed. A total of 30 subjects were studied: 15 normal volunteers, 10 patients with major depression, and 5 recently‐abstinent, alcohol‐dependent patients. Overall, we observed an average intra‐subject correlation of +.273 (PP=0.0001) and +.959 (P=0.005) in the depressed and abstinent alcoholic patients, respectively. These inter‐individual correlations were significantly greater than that seen within the group of normal volunteers ® = + .318, n.s.). The present data suggest that interactions between CCK and CRH are significant in the human CNS, particularly perhaps in depressed and alcoholic patients, and that CSF samples may be used to assess elements of the relationship between these hormones. Depression and Anxiety 10:77–80, 1999. Published 1999 Wiley‐Liss, Inc.


  • Cerebrospinal fluid neuroendocrinology of alcohol misusers

    by Thomas D. Geracioti, R. Jeffrey Goldsmith, Loren M. Friedman, Andrew B. Norman, Eugene Somoza, John W. Kasckow, Dewleen G. Baker, Neil M. Richtand, Robert M. Anthenelli, Paul E. Keck

    Cerebrospinal fluid (CSF) neurohumors reflect central nervous system physiology in a way that peripheral indices can not. We reviewed clinical studies of CSF biogenic amines and neurohormones in alcohol misusers during various stages of withdrawal or abstinence and found them difficult to compare because of highly variable experimental methods, reliance on single time collections (lumbar punctures) that fail to control for potential stress-induced effects of the procedure, lack of control for tobacco use, and a paucity of non-alcoholmisusing controls. However, taken together, the data thus far show that a variety of neuroactive substances are reduced in concentration in the CSF of some alcohol misusers. Low CSF levels of corticotropinreleasing hormone, beta-endorphin, norepinephrine, diazepam-binding inhibitor, 5-hydroxyindoleacetic acid and somatostatin have all been reported. Whether the decreased CSF levels of these neurohormones and neurotransmitters are a cause or consequence of alcoholism has not been determined. In fact, further studies using serial or continuous CSF sampling techniques with homogeneous, better-characterized patients and normal volunteers are still needed to establish the precise CSF neurochemical abnormalities in alcohol misusers.